PTC Therapeutics Inc (NAS:PTCT)
$ 44.185 -0.435 (-0.97%) Market Cap: 3.41 Bil Enterprise Value: 2.83 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 65/100

PTC Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 08:15PM GMT
Release Date Price: $53.07 (-1.06%)
Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

Good afternoon, everyone. I'm Andrew Galler, one of the biotech analysts here at Morgan Stanley, and I'm pleased to be joined today from PTC Therapeutics, Matt Klein, COO; and Kylie O'Keefe, who is the Head of Communications and Global Corporate Strategy.

So I think -- and then before we get started, I want to read out some disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

So to start off, I think that PTC is really in a transformational period right now, based on some of the recent milestones you hit and then also some upcoming data catalysts. So maybe if you want to take a few minutes to start to just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot